Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic–pharmacodynamic modelling ofN-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor

Small molecule c-Met kinase inhibitors: a review of recent patents

(2010) John Porter   EXPERT OPINION ON THERAPEUTIC PATENTS

Novel Agents on the Horizon for Cancer Therapy

(2009) W. W. Ma et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

(2009) T. Y. Seiwert et al.   CANCER RESEARCH

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase–2 and –7 and E-cadherin

(2009) Yasuyoshi Miyata et al.   HUMAN PATHOLOGY

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

(2009) M. G. Ponzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges

(2009) Xiangdong Liu et al.   TRENDS IN MOLECULAR MEDICINE

Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer

(2008) A. Gupta et al.   CLINICAL CANCER RESEARCH

Targeting the c-MET signaling pathway for cancer therapy

(2008) Xiangdong Liu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS